Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma
Journal of Allergy and Clinical Immunology · 2024
DOI: 10.1016/j.jaci.2023.09.043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2024. Verfasst von Eun-Kyung Kwon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Asthma, Camphanes, Endocannabinoids, Oleic Acids. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Oleoylethanolamide (OEA), an endogenously generated cannabinoid-like compound, has been reported to be increased in patients with severe asthma and aspirin-exacerbated respiratory disease. Recruitment of activated eosinophils in the airways is a hallmark of bronchial asthma. OBJECTIVE: We explored the direct contribution of cannabinoid receptor 2 (CB2), a cognate receptor of OEA, which induces eosinophil activation in vitro and in vivo. METHODS: We investigated OEA signaling in the eosinophilic cell line dEol-1 in peripheral blood eosinophils from people with asthma. In order to confirm whether eosinophil activation by OEA is CB2 dependent or not, CB2 small interfering RNA and the CB2 antagonist SR144528 were used. The numbers of airway inflammatory cells and the levels of cytokines were measured in bronchoalveolar lavage fluid, and airway hyperresponsiveness was examined in the BALB/c mice. RESULTS: CB2 expression was increased after OEA treatment in both peripheral blood eosinophils and dEol-1 cells. It was also elevated after OEA-induced recruitment of eosinophils to the lungs in vivo. However, SR144528 treatment reduced the activation of peripheral blood eosinophils from asthmatic patients. Furthermore, CB2 knockdown decreased the activation of dEol-1 cells and the levels of inflammatory and type 2 cytokines. SR144528 treatment alleviated airway hyperresponsiveness and eosinophil recruitment to the lungs in vivo. CONCLUSION: CB2 may contribute to the pathogenesis of eosinophilic asthma. Our results provide new insight into the molecular mechanism of signal transduction by OEA in eosinophilic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
- Department of Biomaterials Science, College of Natural Resources and Life Science, Pusan National University, Miryang, Korea.
- Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
- Department of Pulmonary, Allergy, and Critical Care Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea; Allergy and Clinical Immunology Research Center, Hallym University Colle…
Zitieren
APA
Kwon, E. K., Choi, Y., Sim, S., Ye, Y. M., Shin, Y. S., Park, H. S., & Ban, G. Y. (2024). Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.09.043
Vancouver
Kwon EK, Choi Y, Sim S, Ye YM, Shin YS, Park HS, et al. Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma. Journal of Allergy and Clinical Immunology. 2024. doi:10.1016/j.jaci.2023.09.043
BibTeX
@article{Kwon2024,
author = {Kwon, Eun-Kyung and Choi, Youngwoo and Sim, Soyoon and Ye, Young-Min and Shin, Yoo Seob and Park, Hae-Sim and Ban, Ga-Young},
title = {Cannabinoid receptor 2 as a regulator of inflammation induced oleoylethanolamide in eosinophilic asthma},
journal = {Journal of Allergy and Clinical Immunology},
year = {2024},
doi = {10.1016/j.jaci.2023.09.043}
}
EUVIMED